Form 8-K - Current report:
SEC Accession No. 0001641172-25-015874
Filing Date
2025-06-20
Accepted
2025-06-20 17:00:55
Documents
20
Period of Report
2025-06-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 59224
2 EX-3.1 ex3-1.htm EX-3.1 122071
3 EX-10.1 ex10-1.htm EX-10.1 233058
4 EX-10.2 ex10-2.htm EX-10.2 114237
5 EX-10.3 ex10-3.htm EX-10.3 111430
6 EX-10.4 ex10-4.htm EX-10.4 116810
7 EX-99.1 ex99-1.htm EX-99.1 16703
8 GRAPHIC ex99-1_001.jpg GRAPHIC 6751
  Complete submission text file 0001641172-25-015874.txt   1148321

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE cycc-20250620.xsd EX-101.SCH 3743
10 XBRL DEFINITION FILE cycc-20250620_def.xml EX-101.DEF 26581
11 XBRL LABEL FILE cycc-20250620_lab.xml EX-101.LAB 36613
12 XBRL PRESENTATION FILE cycc-20250620_pre.xml EX-101.PRE 25205
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5897
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 251062162
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)